Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials

The study seeks to delve into the firsthand experiences of patients diagnosed with rhabdomyosarcoma who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.

The data collected from this study will help improve future outcomes for all rhabdomyosarcoma patients as well as those in under-represented demographic groups.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Rhabdomyosarcoma Myosarcoma Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Neoplasms, Muscle Tissue Sarcoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Power Life Sciences

San Francisco, California, 94107, United States

Location contact

Michael B Gill

CONTACT

https://www.withpower.com/[email protected]

415-900-4227

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of rhabdomyosarcoma
Considered reliable, able to understand, and willing to perform all study procedures
Signed Written Informed Consent

Exclusion criteria

Currently enrolled in, have completed or have discontinued from a clinical trial involving an investigational drug
Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
Any serious and/or unstable pre-existing medical disorders

Treatment and study plan

Primary outcomes

Number of rhabdomyosarcoma patients who decide to enroll in a clinical trial

Time frame: 3 months
Rate of rhabdomyosarcoma patients who remain in clinical trial to trial completion

Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Michael B Gill

CONTACT

[email protected]

(415) 900-4227

Sponsors and collaborators

Lead sponsor

Power Life Sciences Inc.

Industry

Registry information

Official study title

Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials: A Study of Participation Patterns Among Those Affected by the Disorder

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Sep 8, 2023
Registry last updated: Sep 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting